Home
NICE Guidance
Conditions and diseases
Urological conditions
Prostate cancer
Explore
Register as a stakeholder
Show sections
8 new
and
0 updated
products since January 2017.
NICE Pathways - mapping our guidance
Bladder cancer
Lung cancer
Prostate cancer
Renal cancer
Suspected cancer recognition and referral
Technology appraisal guidance
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
(TA259)
June 2012
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
(TA387)
April 2016
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
(TA391)
May 2016
Degarelix for treating advanced hormone-dependent prostate cancer
(TA404)
August 2016
Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
(TA101)
June 2006
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
(TA316)
July 2014
Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
(TA377)
January 2016
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
(TA412)
September 2016
Interventional procedures guidance
Cryotherapy as a primary treatment for prostate cancer
(IPG145)
November 2005
Cryotherapy for recurrent prostate cancer
(IPG119)
May 2005
Focal therapy using cryoablation for localised prostate cancer
(IPG423)
April 2012
Focal therapy using high-intensity focused ultrasound for localised prostate cancer
(IPG424)
April 2012
High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer
(IPG174)
May 2006
High-intensity focused ultrasound for prostate cancer
(IPG118)
March 2005
Intraoperative red blood cell salvage during radical prostatectomy or radical cystectomy
(IPG258)
April 2008
Irreversible electroporation for treating prostate cancer
(IPG572)
December 2016
Laparoscopic radical prostatectomy
(IPG193)
November 2006
Low dose rate brachytherapy for localised prostate cancer
(IPG132)
July 2005
Transperineal template biopsy and mapping of the prostate
(IPG364)
October 2010
Diagnostics guidance
Diagnosing prostate cancer: PROGENSA PCA3 assay and Prostate Health Index
(DG17)
June 2015
NICE
Evidence summaries
Hormone-sensitive metastatic prostate cancer: docetaxel
(ESUOM50)
January 2016
Prostate cancer: triptorelin (Decapeptyl SR)
(ESNM30)
January 2014
NICE
Guidelines
Improving outcomes in urological cancers
(CSG2)
September 2002
Prostate cancer: diagnosis and management
(CG175)
January 2014
Suspected cancer: recognition and referral
(NG12)
June 2015
NICE
Medtech innovation briefings
Prolaris gene expression assay for assessing long-term risk of prostate cancer progression
(MIB65)
May 2016
The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer
(MIB16)
December 2014
Quality standards
Prostate cancer
(QS91)
June 2015
Suspected cancer
(QS124)
June 2016
In development
Abiraterone for treating newly diagnosed metastatic hormone-naive prostate cancer [ID945]
(GID-TA10122)
September 2018
Technology appraisal guidance
Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer
(GID-IPG10018)
TBC
Interventional procedures guidance
Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]
(GID-TAG300)
TBC
Technology appraisal guidance
Prostate cancer (hormone refractory) - atrasentan [ID390]
(GID-TAG379)
TBC
Technology appraisal guidance
Prostate cancer (localised) - padeliporfin [ID866]
(GID-TA10067)
August 2018
Technology appraisal guidance
Prostate cancer (prevention) - dutasteride [ID75]
(GID-TAG409)
TBC
Technology appraisal guidance
Prostate cancer: diagnosis and management (update)
(GID-NG10057)
January 2019
NICE guidelines
Use of a hydrogel perirectal spacer during radiotherapy for prostate cancer
(GID-IPG10007)
TBC
Interventional procedures guidance
Guidance
Resources
Savings and productivity
Local practice